GlassScriptPhysician profile
Phillip M Bruner
NPI 1114902590
$645.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $80.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $197.31 | 2019-2020 | |
| Astellas Pharma US INC | $117.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.77 | 2019 | |
| Abbvie INC. | $30.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.15 | 2020 | |
| Boston Scientific Corporation | $13.79 | 2019 | |
| Novo Nordisk INC | $12.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.89 | 2020 | |
| Sanofi Pasteur INC. | $12.31 | 2019 | |
| Glaxosmithkline, LLC. | $12.10 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.10 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Bruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.